NCT02130999View on ClinicalTrials.gov

Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)

PHASE4CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Non-24-Hour-Sleep-Wake Disorder
Interventions
DRUG

tasimelteon 20 mg capsule

DRUG

tasimelteon 2 mg I.V.

Sponsors
All Listed Sponsors
lead

Vanda Pharmaceuticals

INDUSTRY